Denali Therapeutics Inc.
- Jurisdiction
United States - LEI
549300ZTQ2HO18L3Q830 - ISIN
US24823R1059 (DNLI )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Read full profile
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€455.11M - EBIT margin
0.0% - Net income
-€408.59M - Net margin
0.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
|
|
|
|
| Schuth Alexander O. | COFO and Secretary |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| James Anderson |
|
|
|
Sell |
| Peter Brown |
|
|
|
Buy |